Liquid Biopsy blood test in lung cancer diagnosis and monitoring a next generat...
Liquid Biopsy blood test in lung cancer diagnosis and monitoring a next generation noninvasive tumor tracker device
The ultimate objective of the Celletest project is to develop a next generation medical device for non-invasive diagnosis and prognosis of metastatic lung cancer, so we can validate the . To achieve this ambitious objective, we wi...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2020-120306RB-I00
INTEGRAL STAGING, PROGNOSTIC AND DIAGNOSTIC OF CANCER IN LIQ...
184K€
Cerrado
NO-META
Feasibility study of a NOvel METAbolic liquid biopsy for can...
71K€
Cerrado
CTCapture_2.0
Advanced platform for profiling of therapeutic targets and f...
150K€
Cerrado
MAINTRAC-Auto
MAINTRAC Auto Automatization and validation of a liquid bio...
71K€
Cerrado
CytoPro
A breakthrough cancer diagnostic instrument to save 3000 yea...
2M€
Cerrado
Información proyecto CELLETEST
Duración del proyecto: 3 meses
Fecha Inicio: 2015-02-10
Fecha Fin: 2015-06-01
Líder del proyecto
STEM SEL SRL
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The ultimate objective of the Celletest project is to develop a next generation medical device for non-invasive diagnosis and prognosis of metastatic lung cancer, so we can validate the . To achieve this ambitious objective, we will exploit the potential of our proprietary technology for isolation of circulating tumor cells from the bloodstream, so we can validate the clinical utility of CTCs, which have been already identified as biomarkers for the liquid-biopsy of metastatic lung cancers.
What is a Liquid Biopsy? Liquid biopsy is an emerging and disruptive technology in cancer diagnosis, prognosis and monitoring of evolution of cancer patients under anticancer therapies. This novel technology can be understood as the next generation non-invasive alternative to the current gold standard in cancer diagnosis, tissue biopsy. Tissue biopsy implies an interventional/surgical procedure to sample cells or tissue at the tumor site. The biopsied tissue is examined and analyzed (molecular characterization for the determination of the molecular biomarkers of cancer cells) in order to characterize the cancer cells according to their morphological and biochemical properties. This allows determining the tumor typology and prescribing the most optimal anticancer therapy. Liquid biopsy holds promise as a non-invasive method capable to obtain the same clinically relevant information with just a simple blood extraction.